New pill aims to tame tough blood pressure in kidney patients
NCT ID NCT03574363
First seen Jan 05, 2026 · Last updated Jun 20, 2026 · Updated 26 times
Summary
This study tested a new drug called KBP-5074 in 162 people with moderate-to-severe chronic kidney disease whose blood pressure was still high despite treatment. Participants took either a low or high dose of the drug or a placebo daily for 84 days. The main goal was to see if the drug could lower blood pressure more than a placebo, and researchers also checked its safety and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
KBP Biosciences USA Inc
Princeton, New Jersey, 08540, United States
-
Worldwide Clinical Trials
Morrisville, North Carolina, 27560, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KBP-5074 (a mineralocorticoid receptor antagonist) tablet
What this could lead to
If successful, this could lead to a new treatment option to better control blood pressure and possibly slow kidney disease progression in patients with advanced chronic kidney disease.
What could go wrong
This is an early Phase 2 trial with only 162 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects like high potassium or kidney function changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.